 Connection
Joshua Barocas to United States
This is a "connection" page, showing publications Joshua Barocas has written about United States.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.929 |
|
|
|
-
Fetters KB, Padmanabhan P, Yamkovoy K, Guan X, Scott SE, Kerr L, Joseph K, Day GL, Plesons M, Bartholomew TS, Tookes HE, Al-Tayyib A, Barocas JA. Projected Outcomes of Reducing Federal Funding for Syringe Service Programs via Executive Order. JAMA Netw Open. 2026 Jun 01; 9(6):e2619402.
Score: 0.069
-
Kline DM, Padmanabhan P, Brewer SE, Cerdá M, Versen E, Keyes KM, Kushel M, Wilson EC, Wesson P, Hyder A, Boyer A, Al-Tayyib A, Barocas JA. Improving health and housing outcomes through a simulation and economic model: an evidence-based protocol of a group model building approach to develop an agent-based model. Front Public Health. 2025; 13:1623385.
Score: 0.065
-
Mann SC, Barocas JA. Bolstering the HIV Surveillance System Through Innovative Methods, Technologic Advances, and Community-Driven Solutions to Inform Intervention Efforts and End the Epidemic. Curr HIV/AIDS Rep. 2024 Dec 17; 22(1):11.
Score: 0.063
-
Calcaterra SL, Yamkovoy K, Swathi PA, Ciccarone D, Del Pozo B, Englander H, Wang J, Barocas JA. U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015-2019. Drug Alcohol Depend. 2024 09 01; 262:111409.
Score: 0.061
-
Savinkina A, Jurecka C, Gonsalves G, Barocas JA. Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study. Int J Drug Policy. 2023 11; 121:104175.
Score: 0.057
-
Doogan NJ, Mack A, Wang J, Crane D, Jackson R, Applegate M, Villani J, Chandler R, Barocas JA. Opioid Use Disorder Among Ohio's Medicaid Population: Prevalence Estimates From 19 Counties Using a Multiplier Method. Am J Epidemiol. 2022 11 19; 191(12):2098-2108.
Score: 0.054
-
Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clin Infect Dis. 2022 08 24; 75(1):e1112-e1119.
Score: 0.053
-
Barocas JA, Gai MJ, Nurani A, Bagley SM, Hadland SE. Initiation of HIV pre-exposure prophylaxis among youth in the United States, 2015-2018. AIDS Care. 2023 03; 35(3):431-436.
Score: 0.052
-
Bettano A, Del Pozo B, Bernson D, Barocas JA. Stimulant-related incident surveillance using emergency medical service records in Massachusetts, 2013-2020. Drug Alcohol Depend. 2022 06 01; 235:109460.
Score: 0.052
-
Barocas JA, Eftekhari Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clin Infect Dis. 2021 12 06; 73(11):e3661-e3669.
Score: 0.051
-
Hadland SE, Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Morgan JR, Barocas JA. Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction. 2021 10; 116(10):2790-2800.
Score: 0.048
-
Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Hadland SE, Barocas JA. Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex. JAMA Netw Open. 2020 12 01; 3(12):e2030201.
Score: 0.047
-
Schranz A, Barocas JA. Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments. Infect Dis Clin North Am. 2020 09; 34(3):479-493.
Score: 0.046
-
Barocas JA, Tasillo A, Eftekhari Yazdi G, Wang J, Vellozzi C, Hariri S, Isenhour C, Randall L, Ward JW, Mermin J, Salomon JA, Linas BP. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. Clin Infect Dis. 2018 08 01; 67(4):549-556.
Score: 0.040
-
Barocas JA, Wang J, White LF, Tasillo A, Salomon JA, Freedberg KA, Linas BP. Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. Health Aff (Millwood). 2017 12; 36(12):2142-2150.
Score: 0.038
-
Barbosa C, Chen Q, Sahinkoc M, Zarkin GA, Dowd W, Villani J, Barocas JA, Cerdá M, Chatterjee A, Fareed N, Hyder A, Keyes KM, Larochelle MR, Linas BP, Roberts SM, Schackman BR, Seiber E, Wakeman SE, Knudsen AB, Chhatwal J. Impact of enhanced practices on opioid overdose deaths: A community-based modeling approach. Addiction. 2026 Jul; 121(7):1747-1760.
Score: 0.017
-
Dowd WN, Chen Q, Barbosa C, Sahinkoc HM, Barocas J, Chhatwal J, Aldridge AP, Zarkin GA, Knudsen AB. Estimating community-level prevalence of opioid use disorder: Extrapolating from Medicaid claims data and other publicly available data sources in Ohio, USA. Addiction. 2026 Apr; 121(4):944-954.
Score: 0.017
-
Barocas JA, Aldridge A, Adkins KF, Barbosa C, Battaglia TA, Bush J, Castry M, Corry G, Clarke T, El-Bassel N, Figueroa W, Freedman DA, Freisthler B, Gibbons B, Gibson EB, Glasgow L, Harlow K, Huerta TR, Hunt T, Johnson R, Larimore E, Linas BP, Luckey JM, Montoya I, Murphy SM, Oga E, Onuoha E, Orme S, Ryan D, Schackman BR, Seiber EE, Singer M, Speer D, Starbird L, Tin Y, Villani J, Walsh SL, Watson C, Zarkin GA, McCollister K. An economic analysis of community costs incurred to implement the communities that HEAL intervention to reduce opioid overdose deaths in four states. Drug Alcohol Depend. 2025 Jul 01; 272:112671.
Score: 0.016
-
Samet JH, El-Bassel N, Winhusen TJ, Jackson RD, Oga EA, Chandler RK, Villani J, Freisthler B, Adams J, Aldridge A, Angerame A, Babineau DC, Bagley SM, Baker TJ, Balvanz P, Barbosa C, Barocas J, Battaglia TA, Beard DD, Beers D, Blevins D, Bove N, Bridden C, Brown JL, Bush HM, Bush JL, Caldwell R, Calver K, Calvert D, Campbell ANC, Carpenter J, Caspar R, Chassler D, Chaya J, Cheng DM, Cunningham CO, Dasgupta A, David JL, Davis A, Dean T, Drainoni ML, Eggleston B, Fanucchi LC, Feaster DJ, Fernandez S, Figueroa W, Freedman DA, Freeman PR, Freiermuth CE, Friedlander E, Gelberg KH, Gibson EB, Gilbert L, Glasgow L, Goddard-Eckrich DA, Gomori S, Gruss DE, Gulley J, Gutnick D, Hall ME, Harger Dykes N, Hargrove SL, Harlow K, Harris A, Harris D, Helme DW, Holloway J, Hotchkiss J, Huang T, Huerta TR, Hunt T, Hyder A, Ingram VL, Ingram T, Kauffman E, Kimball JL, Kinnard EN, Knott C, Knudsen HK, Konstan MW, Kosakowski S, Larochelle MR, Leaver HM, LeBaron PA, Lefebvre RC, Levin FR, Lewis N, Lewis N, Lofwall MR, Lounsbury DW, Luster JE, Lyons MS, Mack A, Marks KR, Marquesano S, Mauk R, McAlearney AS, McConnell K, McGladrey ML, McMullan J, Miles J, Munoz Lopez R, Nelson A, Neufeld JL, Newman L, Nguyen TQ, Nunes EV, Oller DA, Oser CB, Oyler DR, Pagnano S, Parran TV, Powell J, Powers K, Ralston W, Ramsey K, Rapkin BD, Reynolds JG, Roberts MF, Robertson W, Rock P, Rodgers E, Rodriguez S, Rudorf M, Ryan S, Salsberry P, Salvage M, Sabounchi N, Saucier M, Savitzky C, Schackman B, Schady E, Seiber EE, Shadwick A, Shoben A, Slater MD, Slavova S, Speer D, Sprunger J, Starbird LE, Staton M, Stein MD, Stevens-Watkins DJ, Stopka TJ, Sullivan A, Surratt HL, Sword Cruz R, Talbert JC, Taylor JL, Thompson KL, Vandergrift N, Vickers-Smith RA, Vietze DJ, Walker DM, Walley AY, Walters ST, Weiss R, Westgate PM, Wu E, Young AM, Zarkin GA, Walsh SL. Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths. N Engl J Med. 2024 09 19; 391(11):989-1001.
Score: 0.015
-
Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 09 05; 6(9):e2329583.
Score: 0.014
-
Thompson K, Barocas JA, Delcher C, Bae J, Hammerslag L, Wang J, Chandler R, Villani J, Walsh S, Talbert J. The prevalence of opioid use disorder in Kentucky's counties: A two-year multi-sample capture-recapture analysis. Drug Alcohol Depend. 2023 01 01; 242:109710.
Score: 0.014
-
Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 09; 117(9):2450-2461.
Score: 0.013
-
Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764.
Score: 0.012
-
Springer SA, Barocas JA, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, Del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda. J Infect Dis. 2020 09 02; 222(Suppl 5):S230-S238.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|